Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 13/20 | 0.64 |
| ▸ | PIM1 | P11309 | 4/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | AURKA | O14965 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.49 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.49 |
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4106057 | 0.78 | MAPKAPK2 (0.61) | MAPKAPK2GSK3BCDK2CDC7ROCK2 | |
| SCHEMBL4110478 | 0.78 | MAPKAPK2 (0.61) | MAPKAPK2GSK3BCDK2CDC7ROCK2 | |
| SCHEMBL4111025 | 0.78 | MAPKAPK2 (1.00) | MAPKAPK2PIM1PIM2GSK3BAURKA | |
| SCHEMBL4099265 | 0.76 | MAPKAPK2 (1.00) | MAPKAPK2PIM1PIM2GSK3BAURKA | |
| SCHEMBL4116711 | 0.76 | MAPKAPK2 (0.76) | MAPKAPK2PIM1PIM2GSK3BAURKA | |
| SCHEMBL4106207 | 0.76 | MAPKAPK2 (0.64) | MAPKAPK2GSK3BCDK2CDC7ROCK2 | |
| SCHEMBL18342008 | 0.75 | MAPKAPK2 (0.76) | MAPKAPK2PIM1PIM2GSK3BKIT | |
| SCHEMBL4112051 | 0.75 | MAPKAPK2 (1.00) | MAPKAPK2PIM1PIM2GSK3BAURKA | |
| SCHEMBL4112047 | 0.75 | MAPKAPK2 (1.00) | MAPKAPK2PIM1PIM2GSK3BAURKA | |
| SCHEMBL4107091 | 0.74 | MAPKAPK2 (0.63) | MAPKAPK2PIM1PIM2GSK3BAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG | 2009-07-02 | — | — | US | disclosed |
| CN-101277962-A | Bicyclic aromatic compounds useful as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 | NOVARTIS PHARMA AG (CH) | 2008-10-01 | — | — | CN | disclosed |
| EP-1934223-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | Novartis Pharma AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039285-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169558-A1 | BICYCLIC AROMATIC COMPOUNDS USEFUL AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 | MAP4K2, MAPKAPK2, MAP3K2 | MAPKAPK2 2/4885PIM1 362/4885PIM2 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.